Hamden, Connecticut -- Medical technology company Brain Tunnelgenix has secured $9.1 million in equity venture capital funding, according to an SEC filing.
Brain Tunnelgenix has developed the ability to continuously measure human body temperature from a device located outside the body.
The company's product is the Abreu BTT 700 System, which determines temperature at a space located between the eye and the eyebrow, an area that lacks insulation tissue.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
Brain Tunnelgenix is still seeking $851,000 in additional financing, according to the filing.
Minimum investment size per investor was listed as $10,000.